Back to search

Peptide record

TPDB19357

Antibacterial standard
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB19357
Antibacterial
Anti-infective peptides
Peptipedia
standard
No
A 8-aa standard natural antibacterial peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
FLKSNALL
Physicochemical Analysis
C43H72N10O11
RDCEQGHIMPTWYV
L
905.11
10.10
1
0
5
+1
-1.44
0.975
158.75
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
3
L
1
K
0
M
1
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 1 M: 0 F: 1 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
8
C43H72N10O11
905.11
10.10
+1
-1.44
0.975
Evidence Records 14 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.125-2 µg/mL

Target

Staphylococcus aureus susceptible and resistant strains NCTC 8325 NRS108 NRS71 MRSA Mu50 VISA

Source & Reference

NA

Other

Active against primarily Gram-positive pathogens, S. aureus susceptible and resistant strains NCTC 8325 NRS108 NRS71 MRSA Mu50 VISA (MIC 0.125-2 ug/ml), S. epidermidis ATCC 35982 or NRS8 (MIC 0.5 ug/ml), S. haemolyticus NRS9 or NRS69 (MIC 0.
Evidence 2 Activity

Activity

MIC
Antibacterial
0.5 µg/mL

Target

Staphylococcus epidermidis ATCC 35982 or NRS8

Source & Reference

NA

Other

ceptible and resistant strains NCTC 8325 NRS108 NRS71 MRSA Mu50 VISA (MIC 0.125-2 ug/ml), S. epidermidis ATCC 35982 or NRS8 (MIC 0.5 ug/ml), S. haemolyticus NRS9 or NRS69 (MIC 0.5-1 ug/ml), E. faecium BM4147 VRE (MIC 0.5-2 ug/ml)
Evidence 3 Activity

Activity

MIC
Antibacterial
0.5-1 µg/mL

Target

Staphylococcus haemolyticus NRS9 or NRS69

Source & Reference

NA

Other

71 MRSA Mu50 VISA (MIC 0.125-2 ug/ml), S. epidermidis ATCC 35982 or NRS8 (MIC 0.5 ug/ml), S. haemolyticus NRS9 or NRS69 (MIC 0.5-1 ug/ml), E. faecium BM4147 VRE (MIC 0.5-2 ug/ml), anti-VRE, B. subtilis 1A1 or 168 (MIC 1-2 ug/ml
Evidence 4 Activity

Activity

MIC
Antibacterial
0.5-2 µg/mL

Target

E. faecium BM4147 VRE

Source & Reference

NA

Other

idis ATCC 35982 or NRS8 (MIC 0.5 ug/ml), S. haemolyticus NRS9 or NRS69 (MIC 0.5-1 ug/ml), E. faecium BM4147 VRE (MIC 0.5-2 ug/ml), anti-VRE, B. subtilis 1A1 or 168 (MIC 1-2 ug/ml), B. anthracis Sterne (MIC 0.25 ug/ml),
Evidence 5 Activity

Activity

MIC
Antibacterial
1-2 µg/mL

Target

B. subtilis 1A1 or 168

Source & Reference

NA

Other

ticus NRS9 or NRS69 (MIC 0.5-1 ug/ml), E. faecium BM4147 VRE (MIC 0.5-2 ug/ml), anti-VRE, B. subtilis 1A1 or 168 (MIC 1-2 ug/ml), B. anthracis Sterne (MIC 0.25 ug/ml), S. pneumoniae ATCC10813 (MIC 0.25-0.5 ug/ml), S. p
Evidence 6 Activity

Activity

MIC
Antibacterial
0.25 µg/mL

Target

B. anthracis Sterne

Source & Reference

NA

Other

. faecium BM4147 VRE (MIC 0.5-2 ug/ml), anti-VRE, B. subtilis 1A1 or 168 (MIC 1-2 ug/ml), B. anthracis Sterne (MIC 0.25 ug/ml), S. pneumoniae ATCC10813 (MIC 0.25-0.5 ug/ml), S. pyogenes ATCC19615 (MIC 0.25-0.5 ug/ml)
Evidence 7 Activity

Activity

MIC
Antibacterial
0.25-0.5 µg/mL

Target

S. pneumoniae ATCC10813

Source & Reference

NA

Other

, anti-VRE, B. subtilis 1A1 or 168 (MIC 1-2 ug/ml), B. anthracis Sterne (MIC 0.25 ug/ml), S. pneumoniae ATCC10813 (MIC 0.25-0.5 ug/ml), S. pyogenes ATCC19615 (MIC 0.25-0.5 ug/ml), S. warneri NRS138 (MIC 1 ug/ml), M. smegmati
Evidence 8 Activity

Activity

MIC
Antibacterial
0.25-0.5 µg/mL

Target

Streptococcus pyogenes ATCC19615

Source & Reference

NA

Other

/ml), B. anthracis Sterne (MIC 0.25 ug/ml), S. pneumoniae ATCC10813 (MIC 0.25-0.5 ug/ml), S. pyogenes ATCC19615 (MIC 0.25-0.5 ug/ml), S. warneri NRS138 (MIC 1 ug/ml), M. smegmatis MC2 155 (MIC 2 ug/ml), M. tuberculosis MC2
Evidence 9 Activity

Activity

MIC
Antibacterial
1 µg/mL

Target

Staphylococcus warneri NRS138

Source & Reference

NA

Other

S. pneumoniae ATCC10813 (MIC 0.25-0.5 ug/ml), S. pyogenes ATCC19615 (MIC 0.25-0.5 ug/ml), S. warneri NRS138 (MIC 1 ug/ml), M. smegmatis MC2 155 (MIC 2 ug/ml), M. tuberculosis MC2 6020 (MIC 0.5-1 ug/ml), Gram- H.
Evidence 10 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

M. smegmatis MC2 155

Source & Reference

NA

Other

-0.5 ug/ml), S. pyogenes ATCC19615 (MIC 0.25-0.5 ug/ml), S. warneri NRS138 (MIC 1 ug/ml), M. smegmatis MC2 155 (MIC 2 ug/ml), M. tuberculosis MC2 6020 (MIC 0.5-1 ug/ml), Gram- H. influenzae SJ7 (MIC 2 ug/ml), E. co
Evidence 11 Activity

Activity

MIC
Antibacterial
0.5-1 µg/mL

Target

M. tuberculosis MC2 6020

Source & Reference

NA

Other

MIC 0.25-0.5 ug/ml), S. warneri NRS138 (MIC 1 ug/ml), M. smegmatis MC2 155 (MIC 2 ug/ml), M. tuberculosis MC2 6020 (MIC 0.5-1 ug/ml), Gram- H. influenzae SJ7 (MIC 2 ug/ml), E. coli K12 (MIC 64 ug/ml), and P.aeruginosa PA-0
Evidence 12 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

H. influenzae SJ7

Source & Reference

NA

Other

l), M. smegmatis MC2 155 (MIC 2 ug/ml), M. tuberculosis MC2 6020 (MIC 0.5-1 ug/ml), Gram- H. influenzae SJ7 (MIC 2 ug/ml), E. coli K12 (MIC 64 ug/ml), and P.aeruginosa PA-01 (MIC >128 ug/ml).
Evidence 13 Activity

Activity

MIC
Antibacterial
64 µg/mL

Target

Escherichia coli K12

Source & Reference

NA

Other

g/ml), M. tuberculosis MC2 6020 (MIC 0.5-1 ug/ml), Gram- H. influenzae SJ7 (MIC 2 ug/ml), E. coli K12 (MIC 64 ug/ml), and P.aeruginosa PA-01 (MIC >128 ug/ml).
Evidence 14 Activity

Activity

MIC
Antibacterial
>128 µg/mL

Target

P.aeruginosa PA-01

Source & Reference

NA

Other

(MIC 0.5-1 ug/ml), Gram- H. influenzae SJ7 (MIC 2 ug/ml), E. coli K12 (MIC 64 ug/ml), and P.aeruginosa PA-01 (MIC >128 ug/ml).